Basilea Pharmaceutica AG (BPMUF)
USD 52.83
(0.0%)
USD 52.83
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 157.63 Million CHF | 6.68% |
| 2022 | 147.76 Million CHF | -0.24% |
| 2021 | 148.12 Million CHF | 16.06% |
| 2020 | 127.62 Million CHF | -5.02% |
| 2019 | 134.38 Million CHF | 1.38% |
| 2018 | 132.55 Million CHF | 30.57% |
| 2017 | 101.52 Million CHF | 53.86% |
| 2016 | 65.98 Million CHF | 27.74% |
| 2015 | 51.65 Million CHF | 21.54% |
| 2014 | 42.49 Million CHF | 3.78% |
| 2013 | 40.95 Million CHF | -29.25% |
| 2012 | 57.87 Million CHF | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 38.14 Million CHF | -47.55% |
| 2024 Q2 | 38.14 Million CHF | 0.0% |
| 2023 Q1 | 42.45 Million CHF | -52.36% |
| 2023 Q4 | 72.72 Million CHF | 100.0% |
| 2023 Q3 | 36.36 Million CHF | -57.17% |
| 2023 Q2 | 84.9 Million CHF | 100.0% |
| 2023 FY | 157.63 Million CHF | 6.68% |
| 2022 Q1 | 28.82 Million CHF | -69.31% |
| 2022 Q4 | 89.11 Million CHF | 97.78% |
| 2022 Q3 | 45.05 Million CHF | -23.17% |
| 2022 Q2 | 58.64 Million CHF | 103.47% |
| 2022 FY | 147.76 Million CHF | -0.24% |
| 2021 Q2 | 54.19 Million CHF | 100.0% |
| 2021 Q4 | 93.92 Million CHF | 100.0% |
| 2021 FY | 148.12 Million CHF | 16.06% |
| 2021 Q1 | 27.09 Million CHF | -53.52% |
| 2021 Q3 | 46.96 Million CHF | -13.35% |
| 2020 FY | 127.62 Million CHF | -5.02% |
| 2020 Q1 | 34.66 Million CHF | -51.31% |
| 2020 Q4 | 58.3 Million CHF | 100.0% |
| 2020 Q2 | 69.32 Million CHF | 100.0% |
| 2020 Q3 | 29.15 Million CHF | -57.95% |
| 2019 FY | 134.38 Million CHF | 1.38% |
| 2019 Q4 | 71.19 Million CHF | 100.0% |
| 2019 Q1 | 31.59 Million CHF | -13.06% |
| 2019 Q3 | 35.59 Million CHF | -43.66% |
| 2019 Q2 | 63.18 Million CHF | 100.0% |
| 2018 FY | 132.55 Million CHF | 30.57% |
| 2018 Q3 | 36.33 Million CHF | 21.38% |
| 2018 Q2 | 29.93 Million CHF | 0.0% |
| 2018 Q1 | 29.93 Million CHF | 8.24% |
| 2018 Q4 | 36.33 Million CHF | 0.0% |
| 2017 Q1 | 23.1 Million CHF | 27.5% |
| 2017 Q4 | 27.66 Million CHF | 0.0% |
| 2017 FY | 101.52 Million CHF | 53.86% |
| 2017 Q2 | 23.1 Million CHF | 0.0% |
| 2017 Q3 | 27.66 Million CHF | 19.74% |
| 2016 Q2 | 14.87 Million CHF | 0.0% |
| 2016 Q3 | 18.11 Million CHF | 21.8% |
| 2016 Q4 | 18.11 Million CHF | 0.0% |
| 2016 FY | 65.98 Million CHF | 27.74% |
| 2016 Q1 | 14.87 Million CHF | 6.09% |
| 2015 FY | 51.65 Million CHF | 21.54% |
| 2015 Q3 | 14.02 Million CHF | 13.13% |
| 2015 Q2 | 12.39 Million CHF | 0.0% |
| 2015 Q1 | 12.39 Million CHF | 11.33% |
| 2015 Q4 | 14.02 Million CHF | 0.0% |
| 2014 Q2 | 10.11 Million CHF | 0.0% |
| 2014 FY | 42.49 Million CHF | 3.78% |
| 2014 Q4 | 11.13 Million CHF | 0.0% |
| 2014 Q3 | 11.13 Million CHF | 10.02% |
| 2014 Q1 | 10.11 Million CHF | -1.19% |
| 2013 Q3 | 10.23 Million CHF | 0.04% |
| 2013 FY | 40.95 Million CHF | -29.25% |
| 2013 Q4 | 10.23 Million CHF | 0.0% |
| 2013 Q2 | 10.23 Million CHF | -0.0% |
| 2013 Q1 | 10.23 Million CHF | -23.29% |
| 2012 FY | 57.87 Million CHF | 0.0% |
| 2012 Q3 | 13.34 Million CHF | 0.0% |
| 2012 Q4 | 13.34 Million CHF | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -205256.887% |
| CSL Limited | 14.69 Billion USD | 98.927% |
| Eiger BioPharmaceuticals, Inc. | 15.77 Million USD | -899.391% |
| Nanobac Pharmaceuticals, Incorporated | 17.62 Thousand USD | -894480.33% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| Evofem Biosciences, Inc. | 18.21 Million USD | -765.265% |
| Santhera Pharmaceuticals Holding AG | 122.95 Million USD | -28.206% |
| Propanc Biopharma, Inc. | - USD | -Infinity% |
| Mesoblast Limited | 5.9 Million USD | -2570.857% |
| Marizyme, Inc. | 645.81 Thousand USD | -24308.727% |
| Genus plc | 668.8 Million USD | 76.43% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -38331.851% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| IMV Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 39.51 Thousand USD | -398791.644% |
| MultiCell Technologies, Inc. | 49.32 USD | -319614660.746% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 49.72 Million USD | -217.037% |
| EV Biologics, Inc. | 48.9 Thousand USD | -322259.918% |
| Q BioMed Inc. | 284.35 Thousand USD | -55336.22% |
| Emmaus Life Sciences, Inc. | 29.59 Million USD | -432.601% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -225091.429% |
| Skye Bioscience, Inc. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 21.47 Million USD | -633.932% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 75.72 Thousand USD | -208069.141% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -239727.775% |
| Acro Biomedical Co., Ltd. | 658.5 Thousand USD | -23838.345% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 245.31 Million USD | 35.742% |
| Therapeutic Solutions International, Inc. | 98.99 Thousand USD | -159135.913% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| argenx SE | 1.22 Billion USD | 87.146% |
| HST Global, Inc. | - USD | -Infinity% |
| Halberd Corporation | 999.00 USD | -15779079.179% |
| Enzolytics Inc. | 52.79 Thousand USD | -298471.862% |
| Resverlogix Corp. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 608.52 Thousand USD | -25804.277% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 1.93 Million USD | -8059.11% |
| American Oriental Bioengineering, Inc. | 145.09 Million USD | -8.638% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Provectus Biopharmaceuticals, Inc. | 557.71 Thousand USD | -28164.51% |
| Endonovo Therapeutics, Inc. | 140.24 Thousand USD | -112301.42% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -25432.57% |
| ONE Bio Corp. | 52.29 Million USD | -201.425% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 839.52 Million USD | 81.224% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | - USD | -Infinity% |
| Helix BioMedix, Inc. | 997.72 Thousand USD | -15699.328% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 48.35 Million USD | -226.0% |
| BioStem Technologies, Inc. | 16.68 Million USD | -844.742% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -66535.949% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -66535.949% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.36 Million USD | -11414.536% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| CytoDyn Inc. | - USD | -Infinity% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 473.73 Thousand USD | -33175.072% |
| SYBLEU INC | 11.69 Thousand USD | -1347659.918% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| International Stem Cell Corporation | 7.78 Million USD | -1923.803% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 13 Thousand USD | -1212469.231% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | - USD | -Infinity% |
| Neutra Corp. | 39.53 Thousand USD | -398630.207% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| PureTech Health plc | 3.33 Million USD | -4633.754% |
| Coeptis Therapeutics, Inc. | - USD | -Infinity% |
| IXICO plc | 6.66 Million USD | -2265.101% |
| IntelGenx Technologies Corp. | 1.03 Million USD | -15071.704% |
| Gelesis Holdings, Inc. | 25.76 Million USD | -511.767% |
| CSL Limited | 14.8 Billion USD | 98.935% |
| Cellectis S.A. | 755 Thousand USD | -20778.675% |